Running title: SYD985 is effective in low HER2-expressing breast cancer. At pH conditions relevant for tumors, cathepsin-B cleavage studies showed efficient release of the active toxin by SYD985 but not by T-DM1. These in vitro data suggest that SYD985 might be a more potent ADC in HER2 expressing tumors in vivo, especially in low HER2-expressing and/or in heterogeneous tumors. In line with this, in vivo anti-tumor studies in breast cancer PDX models showed that SYD985 is very active in HER2 3+, 2+, and 1+ models whereas T-DM1 only showed significant anti-tumor activity in HER2 3+ breast cancer PDX models. These properties of SYD985 may enable expansion of the target population to patients who have low HER2 expressing breast cancer, a patient population with still unmet high medical need.
INTRODUCTION
After many years of investigation, antibody-drug-conjugates (ADCs) finally find their way to clinical practice (1) . The approval of the CD30-targeting ADC brentuximab-vedotin (marketed as Adcetris®) for treatment of relapsed Hodgkin's lymphoma and relapsed systemic anaplastic large cell lymphoma (2, 3, 4) and the more recent approval of adotrastuzumab emtansine (T-DM1, marketed as Kadcyla®) for the treatment of HER2-positive metastatic breast cancer (5, 6, 7, 8) , confirm the potential of ADCs in cancer treatment. The promise of ADCs as a new class of drugs in oncology is further illustrated by the fact that currently over 30 ADCs are in clinical development and many more are in preclinical programs (1) .
The approval of T-DM1 was based on studies demonstrating increased progression-free survival and overall survival time of patients with metastatic HER2-positive breast cancer (5, 6, 7, 8) at a dosing regimen (3.6 mg/kg / 3 weeks) that was well tolerated. The introduction of T-DM1 has added great value to the therapeutic armamentarium for patients with HER2-positive metastatic breast cancer; nevertheless, the patient population that might benefit from a HER2-targeting ADC could be expanded by a more effective HER2-targeting ADC. T-DM1 is approved for the treatment of HER2-positive metastatic breast cancers, defined as IHC-HER2 3+ or FISH-positive / IHC-HER2 2+.
According to these criteria, approximately 20% to 25% of all metastatic breast cancer patients are currently eligible for T-DM1 therapy (9, 10) . A HER2-targeting drug that has a clinical benefit in patients whose tumor is FISH-negative but has detectable IHC HER2 expression (2+ and 1+) would at least double that population (10, 11) . same medium. Cell viability was assessed after 6 days, unless indicated otherwise, using the CellTiter-Glo TM (CTG) luminescent assay kit from Promega Corporation (Madison, WI) according to the manufacturer's instructions and as detailed previously (12). Percentage survival was calculated by dividing the measured luminescence for each drug or ADC concentration with the average mean of untreated cells (only growth medium) multiplied by 100.
Fluorescent labeling of SYD985 and T-DM1.

SYD985 and T-DM1 were labeled with an Alexa Fluor® 488 reactive dye from
Invitrogen, which has a tetrafluorophenyl (TFP) ester moiety that reacts efficiently with primary amines of proteins to form stable dye-protein conjugates. Prior to labeling, T-DM1 or SYD985 were desalted into PBS and the protein concentration was determined using UV absorbance at 280 nm. The pH was adjusted to pH 8.3 and labeling was performed by incubation of T-DM1 or SYD985 solution with an Alexa Fluor 488 solution in DMA in a 9:1 molar ratio (dye:mAb) for 1hr. After incubation, labeled T-DM1 or SYD985 was buffer-exchanged into PBS using gel filtration. The degree of labeling was calculated from the UV absorbance at 280 and 495nm according to the documentation supplied with the labeling kit and was found to be 1.4 for SYD985 and 1.8 for T-DM1.
Internalization studies.
Internalization was performed as detailed previously (11) . Cells (2,000,000 cells/tube)
were incubated for 1 hour at 4°C with 2 ml of 3 μg/ml Alexa Fluor 488 (AF488)-labeled SYD985 or 2 ml of 3 μg/ml Alexa Fluor 488-labeled T-DM1. These cells were split into two groups after a wash step with ice-cold 1x PBS (Lonza) Enzymatic cleavage by Cathepsin B 0.1 mg/ml of the ADC or 10 µM active toxin (seco-DUBA) was mixed with 5 µg/ml human liver cathepsin B (Calbiochem) in 0.1M Na-acetate buffer pH 5, 6, 6.5 or 7, supplemented with 4 mM DTT. As a control, ADCs or seco-DUBA were diluted in culture medium to a 0.1 mg/ml concentration. After 4 hours of pre-incubation at 37°C, serial dilutions were made from each stock solution in culture medium and 10 µl was added to each well of a 96-wells plate. SW-620 cells (90 µl; 4,000 cells/well) were cultured with these ADCs or seco-DUBA for 6 days, and the cell viability was measured after 6 days using the CellTiter-Glo TM (CTG) assay kit. 
Bystander killing assay
Cleavage by CES1c
A 100 µg/ml concentration of SYD985 was spiked in human K2-EDTA plasma together with 0, 10, 100, 200 and 400 µg/ml recombinant mouse carboxylesterase 1c (CES1c, Cusabio Biotech, Wuhan, China). After 96 hours of incubation at 37°C, plasma samples were snap frozen in liquid nitrogen and stored at -80°C until bioanalysis. SYD985 ADC (conjugated antibody) levels and total antibody (TAb) levels in plasma were quantified using an ELISA based method as described previously (12).
Cell line and patient-derived xenograft studies
The in vivo anti-tumor activity of SYD985 versus T-DM1 was tested as single dose therapy in the BT-474 cell-line derived xenograft model, and a selection of breast cancer patient-derived xenografts (PDX tumor and tumors from the PDX models as determined by the CROs were independently confirmed as described below in this materials and methods section. The characteristics of all tumors used in this paper are summarized in Supplement Table S1 .
Representative photographs of the HER2 IHC staining are presented in Supplement Figure S2 . Studies were conducted as detailed previously (12).
HER2 Gene amplification.
HER2/neu gene amplification was determined by in situ hybridization (ISH) in formalin- 
Statistical analysis
Statistical analyses of in vitro cytotoxicity assays and in vivo xenograft experiments were performed as detailed previously (12).
RESULTS
SYD985
SYD985 (Figure 1 ) was synthesized and prepared as described previously (12). In short, vc-seco-DUBA was coupled to cysteine residues of trastuzumab after partial reduction of the interchain disulfides. SYD985 was further purified by Hydrophobic
Interaction Chromatography to deliver a well-defined ADC consisting of predominantly species with a Drug to Antibody Ratio (DAR) of 2 and 4, yielding a mean DAR of 2.8.
Some crucial features of the antibody, such as binding affinity and induction of ADCC activity in vitro were not affected by conjugation (data not shown) as was also published for SYD983, the unfractionated form of SYD985 (12).
Binding and internalization of SYD985 and T-DM1
Binding capacity and percentage of internalization of SYD985 and T-DM1 were Fluorescence of each internalized ADC was measured by flow cytometry after quenching of the surface-bound AF488-labeled ADC with an anti-AF488 antibody. A limitation of this approach is the incomplete quenching of the cell-surface bound AF488-labeled ADCs, as is evident from the 4°C controls. This is in line with the supplier instructions that described a maximum quenching of the AF488 dye up to 90% or lower in the case of conjugated AF488 dye. The kinetics of uptake for SYD985 and T-DM1
were comparable. Also the maximum percentages of internalization for both ADCs are within the same order of magnitude ( Figure 2A ).
Cytotoxicity of SYD985 versus T-DM1 in vitro
A . IC50 values are 6.9 and 15.7 ng/ml in SK-BR-3, 54.1 and 35.9 ng/ml in UACC-893, and 24.5 and 44.9 ng/ml in NCI-N87, for SYD985 and T-DM1, respectively.
Whereas SYD985 and T-DM1 both potently kill UACC-893 cells, we confirmed lack of responsiveness to trastuzumab (Supplement Figure S4B ) (16,17). Importantly, SYD985
retained its activity in cell lines with lower HER2 expression, whereas T-DM1 became less potent with IC50 values of 32.4 and 112.1 ng/ml in SK-OV-3, 67.4 and 313.9 ng/ml in MDA-MB-175-VII, and 14.9 and >1000 ng/ml in ZR-75-1, for SYD985 and T-DM1
respectively (see Supplement Table S2 for % efficacy and 95% CI). Neither SYD985 nor T-DM1 was able to kill HER2-negative SW-620 or NCI-H520 cells ( Figure 2B ), indicating that both ADCs mediate their cytotoxic effect through HER2. Thus, overall these data show that in cell lines with lower HER2 expression (HER2 2+/1+), SYD985 is significantly (factor 3-50) more potent than T-DM1.
Next, we studied the relation between exposure times to ADC and cell killing after 6 days, in three cell lines with different HER2 expression levels. SK-BR-3, SK-OV-3 and MDA-MB-175-VII cells were exposed to SYD985 and T-DM1 for 6 and 24 hours, washed to remove ADCs and cultured until 6 days, except for MDA-MB-175-VII cells (12 days). As control, cells were treated with ADCs during the entire incubation of 6 and 12 days. A short incubation of 6 hr was enough for both SYD985 and T-DM1 to potently kill SK-BR-3 cells after 6 days, indicating that sufficient amounts of the respective toxins were loaded inside cells to induce killing ( Figure 2C ). For SK-OV-3 and MDA-MB-175-VII cells, in line with their lower HER2 expression, a 6 or even 24 hr exposure to ADC did not induce maximum killing, suggesting that re-cycling of HER2 after internalization and re-loading of cells with ADC is needed for potent killing of cells with low HER2 levels ( Figure 2C ).
Protease sensitivity and bystander killing in vitro
Proteases, like cathepsin B, are highly expressed in a wide variety of tumors, including breast cancer tumors, and can also be active extracellularly through secretion by malignant cells (18, 19) . The sensitivity of SYD985 and T-DM1 to cathepsin B cleavage was evaluated at pH 5 to mimic the acidic milieu in lysosomes and at pH 6, 6.5 and 7 to mimic pH in endosomes and tumor environment. SYD985 and T-DM1 were exposed for NCI-H520 cells were insensitive (IC 50 > 50 nM) to SYD985, its isotype control ADC, and T-DM1 but were sensitive for seco-DUBA (IC 50 0.04 nM) ( Figure 3B and Supplement Figure S4D ). As shown in Figure 3B , treatment of SK-BR-3/NCI-H520 and SK-OV-3/NCI-H520 co-cultures with 1 g/ml SYD985 resulted in killing of the HER2 0 NCI-H520 cells, whereas the non-binding isotype control ADC and T-DM1 did not. Coculturing of cells for 6 days resulted in a dissimilar distribution of the % viable HER2-positive and HER2-negative cells, which was indicated by the results of the isotype control ADC and is most likely due to differences in growth rates.
Despite these differences in growth rates, FACS confirmed ( Figure 3C In all PDX studies, in all experimental groups, body-weight was determined twice a week as a measure for toxicity and potential overdosing. None of the animals in any of the experimental groups in any of the PDX studies showed significant change in bodyweight.
Taken together, these data show that, in contrast to T-DM1, SYD985 is active in breast cancer PDX models with low (2+ and 1+) HER2 status.
Plasma kinetics
In vivo plasma kinetics of SYD985 and T-DM1 were studied in BT-474 tumor bearing mice, since, in contrast to results reported for T-DM1 (23,24), we observe a difference in PK between tumor bearing mice and healthy balb/c mice (12). This is probably caused by target mediated drug disposition, dependent on HER-2 expression levels in the tumor model used, and dependent on the degree of saturation of HER-2 target molecules at the given dose.
As shown in Figure 6A and Supplementary Figure S6 ) and monkey (0.52 ml/h/kg).
Remarkably, in monkey conjugated antibody levels were hardly different from total antibody concentrations (clearance of 0.38 ml/h/kg) and T-DM1 concentrations (clearance of 0.64 ml/h/kg) (25), while active toxin (DUBA) plasma levels remain extremely low ( Figure 6B) .Mean Cmax DUBA level was 0.018 ng/ml versus 5.85 ng/ml for DM1 (25) , both dosed at 3 mg/kg ADC in female monkeys.
After T-DM1 administration to mice, ADC clearance is much lower (1.8 -1.7 ml/h/kg) compared to SYD985 (Figure 6A and supplementary Table S3 ). This is in line with published PK data for T-DM1 (24) showing a clearance of 0.75 -0.9 ml/h/kg for T-DM1, especially when taking into account that the tumor model used shows higher clearance compared to non-tumor bearing mice. Unfortunately, a true quantitative comparison of ADC exposure after dosing of T-DM1 or SYD985 is not possible due to differences between and limitations of the bioanalytical tools. Nevertheless, it is clear that SYD985
shows much higher ADC clearance, most likely due to esterase mediated cleavage of the linker drug, although it cannot be ruled out that other causes of deconjugation, like maleimide exchange to albumin, may contribute. As a consequence, a higher formation of naked antibody is seen for SYD985 compared to T-DM1 in mice.
Mechanism of anti-tumor activity in vivo
To evaluate whether the early release of seco-DUBA in mouse plasma after dosing of SYD985 might affect or contributes to anti-tumor activity we performed a pre-dosing study in the MAXF-MX1 and HBCx-34 PDX models. In both models, a pre-treatment of 24 hours with a high dose of trastuzumab blocked anti-tumor activity of an active dose of SYD985 ( Figure 6C-D) . These data confirm for these two models the earlier conclusion that HER2-mediated targeting to the tumor is essential for anti-tumor activity.
It furthermore proves that anti-tumor activity of SYD985 at least in these two models is not driven by the early release of active toxin in mouse plasma as a result of mouse carboxylesterase cleavage.
DISCUSSION
In order to assess the therapeutic value of SYD985 for treatment of breast cancer patients, we compared its preclinical anti-tumor activity head-to-head to that of T-DM1 in a series of high and low HER2-expressing breast cancer PDX models. In addition, we have performed mechanistic studies in vitro comparing SYD985 to T-DM1 for cytotoxic potency, protease sensitivity and bystander induction. a previous publication where efficacy of ADCs with cleavable linkers were shown to be less dependent on target expression than ADCs with non-cleavable linkers (33). This is also illustrated by the observed anti-tumor activity of the non-binding isotype control of SYD985 that indicated that SYD985 mediated anti-tumor activity was not exclusively target mediated.
As was described previously (12), SYD985 shows a poor stability in mouse plasma and consequently poor kinetics in mice leading to a relatively low exposure. We have shown that the poor PK of SYD985 is due to the presence of a mouse-specific carboxylesterase, CES1c, which is not expressed in human or cynomolgus monkey A.
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